- Public Citizen, National Physicians Alliance, Other Civil Society Groups Write Letters in Support of California AB 463
- KEI Notes on California Assembly Health Committee Markup on AB 463 Pharmaceutical Cost Transparency Act of 2015
- KEI Seminars on Drug Pricing: 30 April 2015, Prof. Paul Grootendorst on the Canadian approach to drug pricing
- OCR version of leaked EU document on : "A digital single market strategy for Europe"
- WIPO CDIP 15: Statement of Brazil on evaluation of the Project on Open Collaborative Projects and IP-Based Models
- The CA State Assembly Health Committee staff analysis of AB463; includes who supports and opposes
- KEI statement to WHO 20th Expert Committee on the Selection and Use of Essential Medicines
- State of California considers AB463, a bill to require disclosure of drug development costs, and more economic data
- Sony complains fundraiser: "smells a little bit like a Disney play regarding corp. tax reform"
- Sony referred to "WIPO treaty for blind as "stalking horse" to "denigrate the rights of copyright owners"
Why would blind people get less than the Olympic Committee? Choosing between Convention, Recommendation and DeclarationSubmitted by Manon Ress on 22. March 2010 - 17:24
When I first heard David Mann representing the World Blind Union at the information session of November 2003 SCCR, call for the "creation of international agreements which would allow the unhindered transfer of accessible material created in one country to blind and partially sighted people in another country", I did not know that this issue had been the subject of a WIPO/UNESCO report in 1983, which had then proposed Model Provisions Concer
On March 5, 2010, KEI published documents received from a FOIA request, about a collaboration between the USPTO and Pfizer to hold workshops in India. On March 11, the USPTO responded with a statement of regret concerning the collaboration, which it termed a mistake.
The Business Standard of India has written an article about the USPTO/Pfizer collaboration here:
KEI has access to a recent draft of ACTA. Chapter One, Section B of the agreement provides for "General Definitions." It is interesting that the term "counterfeits" does not have a general definition. The ten defined terms include:
- intellectual property (See below)
- Council (ACTA Oversight Council)
- person (natural or juridical)
- right owner (includes federation or assicaitons that have legal standing or authoirty to assert rights)
WIPO Open-ended Consultations on Copyright Limitations and Exceptions for Persons with Print DisabilitiesSubmitted by thiru on 22. March 2010 - 8:09
On April 23, 2010 and May 27-28, 2010, WIPO will hold open-ended consultations on copyright limitations and exceptions for persons with print disabilities and on the protection of audiovisual performances as mandated by the conclusions of the 19th session of the WIPO Standing Committee on Copyright and Related Rights (SCCR).
The 8th round of the Anti Counterfeiting Trade Agreement (ACTA) negotiations is scheduled to take place in Wellington, New Zealand from April 12-16, 2010. The March 3 draft agenda obtained by KEI provides details of the program, venue and logistics, and also notes that:
New Zealand intends to hold a function for stakeholders and delegates on the evening of Tuesday 13 April from 18.00, which will be an opportunity for stakeholders to meet and interact with ACTA negotiators.
KEI has access to
yet undisclosed sections of the negotiating ACTA text. The text is organized in 6 chapters. The longest is Chapter 2 on "legal framework for enforcement of intellectual property rights." The second longest is Chapter 5, on "Institutional Arrangements." In ten pages of text, the ACTA negotiators have set out a plan to create a new institution to administer, implement and modify ACTA.
(Updated March 17, 2010, 12pm).
KEI has learned that the European Union has proposed language in the ACTA negotiations to require criminal penalties for "inciting, aiding and abetting" certain offenses, including "at least in cases of willful trademark counterfeiting and copyright or related rights piracy on a commercial scale."
The EU proposal is reported on a recent (but still secret) version of the Anti-Counterfeiting Trade Agreement Consolidated Text, and reads as follows:
Below are asks from the 2010 PhRMA submission to the USTR Special 301 list on the topic of drug pricing and reimbursement decisions, and described as 'Market Access Barriers.' In its assertions, PhRMA attack countries for government price negotiations, making use of reference pricing, the insufficient involvement of pharmaceutical companies in setting government pricing policies and the composition of drug formularies, among other things.
See update at the end. ----------
- March 10, 2010. In the Guardian: Ari Emanuel, the co-chief executive of William Morris Endeavor, the biggest Hollywood talent agency, was among several executives attending a meeting in Abu Dhabi, calling for governments to get tough on illegal downloading.
Emanuel, the brother of US presidential adviser Rahm, said the industry was talking to the US government in a bid to introduce a "three strikes and you're out" law to govern illegal downloading.
633 to 13, EU Parliament votes to make ACTA public, and more sensitive to civil liberties and consumer protectionSubmitted by James Love on 10. March 2010 - 12:53
In a stunning 633 to 13 vote, the EU Parliament voted for a resolution on ACTA that addresses a wide range of criticisms that civil society groups have made of the process and substance.
The KEI statement on the EU vote follows:
On July 28, 2006, Jeffrey Kindler replaced Hank McKinnell as CEO of Pfizer. That day the Pfizer stock price closed at $26.11. With the stock trading today at a little more than $17, it would seem that shareholders have lost a significant amount of their investment. Nonetheless, Kindler is doing well.
FOIA document: In 2007, US Ambassador Ralph Boyce was pleased that Abbott withdrew life saving drugs from market in ThailandSubmitted by James Love on 6. March 2010 - 17:26
In 2007, Thailand was involved in a dispute over the granting of compulsory licenses on medicines, including the patents used for Kaletra, an Abbott drug used in the treatment of AIDS. Kaletra is the brand name for a fixed dose combination of lopinavir and ritonavir (LPV/r) -- two drugs invented at Abbott on an NIH grant. In 2007, LPV/r was the preferred combination for protease inhibitor regimes used to treat AIDS.
This from USTR's 2010 Trade Policy Agenda and 2009 Annual Report:
The United States Patent and Trademark Office has a joint program with Pfizer to fund and manage seminars in India on "misconceptions of evergreening" and "the importance of regulatory data protection and patent linkage." KEI has submitted a FOIA request to USPTO on this topic, and received a small installment of documents on Friday. Attached to this blog are 4 pages of documents that we received from two meetings held in Mumbai, India on September 9, 2009. Ten journalists and 15 NGOs attended the meetings.